Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Endo Narcan

Executive Summary

Shortages of naloxone are due to shutdown of DuPont sterile manufacturing facility, Endo explains (1"The Pink Sheet" March 19, p. 16). DuPont says manufacturing facility was closed for routine repair and maintenance. Endo expects production to be resumed by the end of March. DuPont's Manati, Puerto Rico facility received a warning letter in June 2000 for deviations from good manufacturing practices
Advertisement

Related Content

Naloxone shortage
Naloxone shortage
Abbott Doubles Fentanyl Production To Address Hospital Shortages
Abbott Doubles Fentanyl Production To Address Hospital Shortages
Advertisement
UsernamePublicRestriction

Register

PS037543

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel